The Lynx Group

December 2019, Vol 10, No 6

Medicare models for value-based care in oncology started with the Oncology Care Model (OCM), which was launched in July 2016 and will run until June 2021.
Read Article

San Francisco, CA—Personalization of therapy in the treatment of patients with myelodysplastic syndrome (MDS) is focused primarily on risk classification of patients. Once clinical risk has been established, treatment considerations should be informed by features such as disease subtype, prognostic somatic mutations, chromosomal abnormalities, targetable somatic mutations, immunologic features, and patient factors, according to Rafael Bejar, MD, PhD, Assistant Professor of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA.
Read Article

San Francisco, CA—We are in a “golden age” in chronic lymphocytic leukemia (CLL), according to Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City.
Read Article

San Francisco, CA—An increasing number of biosimilars have been approved in the United States, but many clinicians are still poorly informed about what constitutes a biosimilar, and what is involved in their unique pathway to approval, said Andrew D. Zelenetz, MD, PhD, Medical Oncologist, Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York City. He discussed this topic at the NCCN 2019 Hematologic Malignancies meeting.
Read Article

In the phase 2 STORM Part 1 clinical trial, 21% of patients with refractory multiple myeloma had a partial or better response to oral selinexor (Xpovio) plus dexamethasone. Those findings were the basis for the pivotal phase 2 STORM Part 2 study (Chari A, et al. N Engl J Med. 2019;381:727-738).
Read Article

The introduction of BRAF- and MEK-targeted therapies and immune checkpoint inhibitors has significantly improved outcomes in patients with metastatic melanoma. However, many patients have drug resistance—acquired or primary—which results in death from underlying disease.
Read Article

New York, NY—By its very nature, oncology is rife with change, with new research resulting in treatment advances at a rapid pace. Pending federal legislation aimed at reining in prescription drug prices and an upcoming presidential election may introduce yet further changes in oncology. A discussion on these issues was presented at the 2019 AVBCC Summit in October, with a look at the oncology landscape.
Read Article

New York, NY—At the 2019 AVBCC Summit, a panel of payers, moderated by Mike Kolodziej, MD, Vice President, Chief Innovation Officer, ADVI Health, discussed strategies for improving the delivery of value-based cancer care, along with changes on the horizon as payers and providers strive to maximize access to high-quality oncology drugs.
Read Article

New York, NY—With drug-pricing legislations currently before the House and the Senate, the issue of demonstrating value in high-cost drug therapies has become the front and center of the healthcare conversation. Moderator Roger Longman, MA, Co-Founder and Chairman, Real Endpoints LLC, a reimbursement-focused analytics and advisory firm, engaged an expert panel on the topic of value-based agreements during the 2019 AVBCC Summit.
Read Article

New York, NY—Patients with cancer are not just faced with a terrifying disease; they must also surmount an uphill climb when it comes to accessing care. Advocates—some of whom have shared in their experiences as patients—are hard at work to ensure access is a reality. A roundtable discussion of patient advocates at the 2019 AVBCC Summit focused on identifying the major obstacles to care and what can be done to improve patient access.
Read Article

Page 1 of 3

Subscribe to
Value-Based Cancer Care

Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.

I'd like to recieve: